Hanna Sanoff

16PUBLICATIONS
106CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersDisease surveillanceEpidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 29, 2026
COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer.

|Oct 17, 2025
Community-Engaged Approach to Increase Physical Activity Among Black Individuals With Colorectal Cancer: Protocol for a Feasibility Randomized Controlled Trial of the Physical Activity Centers Empowerment Study.

Rachel Hirschey, Jingle Xu, Nathaniel Woodard

|Sep 02, 2025
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.

Rishi Surana, Micaela Morgado, Ashwin Somasundaram

|Jun 05, 2024
A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer.

Hanna K Sanoff, Allison M Deal, Jai Patel

|Jun 03, 2024
Longitudinal patient-reported outcomes on genotype-guided irinotecan dosing: feasibility and clinical relevance.

Jonathan D Sorah, Allison M Deal, Sophia I Stein

|May 24, 2023
Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010-2018.

Christine D Hsu, Louise M Henderson, Bradford E Jackson

Pageof 3

Frequent Collaborators

2 joint publications

Grant R Williams

2 joint publications

Theodore S Hong

2 joint publications

Ethan M Basch

2 joint publications

Allison M Deal